The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 901–1,000 of 1,006
Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide
Zhou, L., Huang, X., Niesvizky, R., Pu, Z., & Xu, G. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000818 · Cited by 14
Small-Molecule Degraders of Cyclin-Dependent Kinase Protein: A Review
Yu, B., Du, Z., Zhang, Y., Li, Z., & Bian, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0154 · Cited by 15
Jian, Y., Gao, W., Geng, C., Zhou, H., Leng, Y., Li, Y., & Chen, W.-M. (2017) · Oncology Letters · doi:10.3892/ol.2017.6502 · Cited by 16
Gaudy, A. M., Atsriku, C., Ye, Y., MacGorman, K., Liu, L., Xue, Y., Surapaneni, S., & Palmisano, M. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03004-w · Cited by 15
Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation
Grygorowicz, M. A., Borycka, I. S., Nowak, E., Paszkiewicz‐Kozik, E., Rymkiewicz, G., Błachnio, K., Biernacka, M., Bujko, M., Walewski, J. A., & Markowicz, S. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0411-8 · Cited by 14
Targeting DUBs to degrade oncogenic proteins
Cremer, A., & Stegmaier, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0728-7 · Cited by 14
Mezigdomide and Multiple Myeloma
Shortt, J. (2023) · New England Journal of Medicine · doi:10.1056/nejme2307370 · Cited by 14
Cai, P., Disraeli, C., Sauter, B., Zhanybekova, S., & Gillingham, D. G. (2025) · Chemical Science · doi:10.1039/d5sc01251a · Cited by 15
Wang, L., Shi, M., Sung, A. Y., Yin, C. C., Bai, Y., & Chen, M. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150916 · Cited by 16
Highly specific intracellular ubiquitination of a small molecule
Li, W., Garcia-Rivera, E., Mitchell, D. C., Chick, J. M., Maetani, M., Bhadoria, R., Knapp, J. M., Misu, R., Matthews, G. M., Shirasaki, R., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02011-1 · Cited by 15
Self-citationChan, A. M., & Fletcher, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00286k · Cited by 13
Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma
Csizmar, C. M., & Ansell, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073302 · Cited by 14
Rogers, J. H., Gupta, R., Reyes, J. M., Gundry, M. C., Medrano, G., Guzman, A. G., Aguilar, R., Conneely, S. E., Song, T., Johnson, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002408 · Cited by 14
Emerging mechanisms of targeted protein degradation by molecular glues
Frere, G. A., de Araujo, E. D., & Gunning, P. T. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.01.001 · Cited by 14
Richardson, P. G. G., Mateos, M., Vangsted, A. J., Ramasamy, K., Abildgaard, N., Ho, P. J., Quach, H., & Bahlis, N. J. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2142564 · Cited by 13
Žemaitis, K., Ghosh, S., Hansson, J., & Subramaniam, A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104662 · Cited by 13
Gordon, M. J., Feng, L., Strati, P., Lee, H. J., Hagemeister, F. B., Westin, J. R., Samaniego, F., Marques-Piubelli, M. L., Vázquez, F. J. V., Parra, E. R., et al. (2023) · Cancer · doi:10.1002/cncr.35114 · Cited by 13
Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs
Winter, G. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00191 · Cited by 13
Zaman, S., Shentu, S., Yang, J., He, J., Orlowski, R. Z., Stellrecht, C. M., & Gandhi, V. V. (2015) · Neoplasia · doi:10.1016/j.neo.2015.01.006 · Cited by 13
Current and Potential Epigenetic Targets in Multiple Myeloma
Pawlyn, C., Kaiser, M., Davies, F. E., & Morgan, G. J. (2014) · Epigenomics · doi:10.2217/epi.14.12 · Cited by 13
Natural products against hematological malignancies and identification of their targets
Xu, Y., Liu, J., Wu, Y., Guo, Q., Sun, H., & Chen, G. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4922-4 · Cited by 13
Self-citationTargeting plasma cells: are we any closer to a panacea for diseases of antibody‐secreting cells?
Low, M. S. Y., Infantino, S., Grigoriadis, G., & Tarlinton, D. M. (2016) · Immunological Reviews · doi:10.1111/imr.12388 · Cited by 14
Seeking Convergence and Cure with New Myeloma Therapies
Choudhry, P., Galligan, D. C., & Wiita, A. P. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.005 · Cited by 13
Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs
Gong, L., Cui, D., Xiong, X., & Zhao, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_19 · Cited by 15
Genomic profiling of multiple myeloma: New insights and modern technologies
Hultcrantz, M. L., Yellapantula, V. D., & Rustad, E. H. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101153 · Cited by 15
Development of a Buchwald–Hartwig Amination for an Accelerated Library Synthesis of Cereblon Binders
Lejava, A., Miseo, G. A., Phan, T., Zhu, J., Powers, H. L., Li, J., Mortensen, D. S., Zapf, C. W., Khambatta, G., Buenviaje, J., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00462 · Cited by 12
Design and Application of Cereblon-Recruiting Prodegraders
Chase, D. H., Stein, A. J., Grinshpun, D. E., Krone, M. W., & Crews, C. M. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05036 · Cited by 13
Antitumor effect of lenalidomide in malignant glioma cell lines
Hanashima, Y., Sano, E., Sumi, K., Ozawa, Y., Yagi, C., Tatsuoka, J., Yoshimura, S., Yamamuro, S., Ueda, T., Nakayama, T., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7543 · Cited by 14
Kim, G. W., Yoo, J. H., Won, H.-R., Yeon, S.-K., Lee, S. W., Lee, D. H., Jeon, Y. H., & Kwon, S. H. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106398 · Cited by 12
Lin, C.-Y., Yu, C.-J., Shen, C., Liu, C., Chao, T., Huang, C., Tseng, L., & Lai, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01812-x · Cited by 12
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
Bouguenina, H., Nicolaou, S., Bihan, Y. L., Bowling, E. A., Calderon, C., Caldwell, J. J., Harrington, B., Hayes, A., McAndrew, C., Mitsopoulos, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107059 · Cited by 13
C2H2 Zinc Finger Transcription Factors Associated with Hemoglobinopathies
Zhang, X., Xia, F., Zhang, X., Blumenthal, R., & Cheng, X. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168343 · Cited by 13
Next-Generation Therapies for Multiple Myeloma
Meermeier, E. W., Bergsagel, P. L., & Chesi, M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-014236 · Cited by 12
Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma
Ye, T., Mishra, A. K., Banday, S., Li, R., Hu, K., Coleman, M. M., Shan, Y., Chowdhury, S., Zhou, L., Pak, M. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114211 · Cited by 13
Aiolos and Lymphocyte Mimicry in Lung Cancer
Terada, L. S., & Liu, Z. (2014) · Molecular & Cellular Oncology · doi:10.4161/mco.29912 · Cited by 14
Ikaros limits follicular B cell activation by regulating B cell receptor signaling pathways
Heizmann, B., Sellars, M., Macias-Garcia, A., Chan, S. H., & Kastner, P. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.060 · Cited by 12
Zhang, L., Bi, E., Hong, S., Qian, J., Zheng, C., Wang, M. L., & Yi, Q. (2015) · Oncotarget · doi:10.18632/oncotarget.5506 · Cited by 13
Gao, S., Geng, C., Song, T., Lin, X., Liu, J., Cai, Z., & Cang, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.761551 · Cited by 13
Dauti, A., Gerstl, B., Chong, S., Chisholm, O., & Anazodo, A. C. (2017) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2016.0084 · Cited by 12
Amphotericin B, an Anti-Fungal Medication, Directly Increases the Cytotoxicity of NK Cells
Kim, N., Choi, J., Park, H., Kim, I., & Kim, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061262 · Cited by 13
Mainolfi, N., & Rasmusson, T. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.005 · Cited by 12
Kriegsmann, K., Baertsch, M., Awwad, M. H. S., Merz, M., Hose, D., Seckinger, A., Jauch, A. S., Becker, N., Benner, A., Raab, M. S., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0174-z · Cited by 12
Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
Fernández‐Lázaro, D., Fernandez-Lazaro, C. I., Caballero-García, A., & Córdova, A. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018001201444 · Cited by 15
Kocoglu, M. H., & Badros, A. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1756258 · Cited by 13
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H., & Kater, A. P. (2020) · Cancers · doi:10.3390/cancers12123837 · Cited by 14
Khan, S. R., Tariq, M., Fayyaz, S. M., Soomar, S. M., & Moosajee, M. (2022) · Leukemia Research Reports · doi:10.1016/j.lrr.2022.100315 · Cited by 12
Storti, P., Toscani, D., Airoldi, I., Marchica, V., Maïga, S., Bolzoni, M., Fiorini, E., Campanini, N., Martella, E., Mancini, C., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.133736 · Cited by 13
Qian, X., Dimopoulos, M. A., Amatangelo, M. D., Bjorklund, C. C., Towfic, F., Flynt, E., Weisel, K. C., Ocio, E. M., Yu, X., Peluso, T., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1485915 · Cited by 12
Hatake, K., Chou, T., Doi, T., Terui, Y., Kato, H., Hirose, T., Seo, S., Pourdehnad, M., Ogaki, Y., Fujimoto, H., et al. (2020) · Cancer Science · doi:10.1111/cas.14704 · Cited by 12
Molecular Design of Novel Protein-Degrading Therapeutics Agents Currently in Clinical Trial
Kacin, E., & Sewduth, R. N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060744 · Cited by 11
Gui, W., Goss, A., & Kodadek, T. J. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07307 · Cited by 12
Zheng, S., Chen, Y., Zhu, Z., Li, N., He, C., Koeffler, H. P., Han, X., Wei, Q., & Xu, L. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500021 · Cited by 11
Rational discovery of molecular glue degraders based on block chemistry
Wei, J., Feng, W., Chen, Q., Li, Q., & Chen, Z. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104480 · Cited by 12
A double-edged sword of neo-substrate degradation in PROTACs
Song, Z., Duan, C., Wu, M., Wang, Z., Pan, Y., Zhang, C., Huang, W., & Zeng, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118253 · Cited by 12
Marotta, A., Kortman, H. M., Interdonato, C., Seeberger, P. H., & Molloy, J. J. (2024) · Chemical Communications · doi:10.1039/d4cc04653f · Cited by 11
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma
Usmani, S. Z., Zhang, Q. H., Stratton, K., Qu, P., Yaccoby, S., Hansen, E., Steward, D., Panozzo, S. B., Petty, N. M., Hoering, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.248 · Cited by 11
Wang, J., Liu, T., Zhao, A., Pan, B., Sun, J. H., Li, J., Zhou, D., Cao, X., & Duan, M. (2022) · Leukemia · doi:10.1038/s41375-022-01555-8 · Cited by 11
Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma
Zuo, X., & Liu, D. (2022) · Hematology · doi:10.1080/16078454.2022.2124694 · Cited by 12
Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma
Anreddy, N., & Hazlehurst, L. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25617 · Cited by 12
Therapeutic targeting of RNA splicing in myelodysplasia
Kim, Y. J., & Abdel-Wahab, O. I. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.007 · Cited by 11
Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase
Holstein, S. A., Hillengaß, J., & McCarthy, P. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9637 · Cited by 11
Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis
Doren, L. V., & Lentzsch, S. (2020) · Acta Haematologica · doi:10.1159/000507724 · Cited by 12
Miyazato, K., Tahara, H., & Hayakawa, Y. (2020) · Cancer Science · doi:10.1111/cas.14538 · Cited by 12
Boosting Immunity against Multiple Myeloma
Lopes, R., Ferreira, B. V., Caetano, J., Barahona, F., Carneiro, E. A., & Joao, C. M. (2021) · Cancers · doi:10.3390/cancers13061221 · Cited by 12
Perspectives on the Development of First-in-Class Protein Degraders
Rambacher, K. M., Calabrese, M. F., & Yamaguchi, M. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0033 · Cited by 11
A review on the treatment of multiple myeloma with small molecular agents in the past five years
Zhang, Z., Liu, X., Zhao, L., Zhou, Y., Shi, J., Chen, W., & Li, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114053 · Cited by 11
Genomic and in silico analyses of CRBN gene and thalidomide embryopathy in humans
Vianna, F. S. L., Kowalski, T. W., Tovo‐Rodrigues, L., Tagliani‐Ribeiro, A., de Godoy, B. A., Fraga, L. R., Sanseverino, M. T. V., Hutz, M. H., & Schüler‐Faccini, L. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.10.003 · Cited by 12
Contribution of Inhibition of Protein Catabolism in Myeloma
Bianchi, G., & Anderson, K. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000349 · Cited by 11
Tumor-derived CK1α mutations enhance MDMX inhibition of p53
Liu, X., Huang, Q., Chen, L., Zhang, H., Schönbrunn, E., & Chen, J. (2019) · Oncogene · doi:10.1038/s41388-019-0979-z · Cited by 11
Modulation of cereblon levels by anti-myeloma agents
Díaz-Rodríguez, E., & Pandiella, A. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1037752 · Cited by 11
Constitutive protein degradation induces acute cell death via proteolysis productsPreprint
Chen, S., Prakash, S., Helgason, E., Gilchrist, C. L., Kenner, L. R., Srinivasan, R., Sterne‐Weiler, T., Hafner, M. A., Piskol, R., Dueber, E. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.06.527237 · Cited by 12
Liu, M., Zhang, Y., Wu, Y., Jin, J., Cao, Y., Fang, Z., Geng, L., Yang, L., Yu, M., Bu, Z., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70960 · Cited by 10
“Dysregulation of IKZF1 is associated with a variety of cancers, 101 including leukemia [16-19], multiple myeloma (MM) [20, 21] and some solid tumors 102 [22, 23].”
BackgroundDiscovery of molecular glues that bind FKBP12 and novel targets using DNA-barcoded libraries
Zandi, T. A., Romanowski, M. J., Viscomi, J. S., Tan, Z. Y., Tong, B., Bonazzi, S., Zécri, F. J., Schreiber, S. L., & Michaud, G. A. (2024) · doi:10.1101/2024.12.09.627499 · Cited by 10
Figg, J., Barajas, J. M., & Obeng, E. A. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000632 · Cited by 10
Jang, J., Kim, J.-Y., & Lee, T. J. (2024) · Genes & Genomics · doi:10.1007/s13258-024-01565-z · Cited by 11
Koh, M. Y., Chung, T., Tang, N. X. N., Toh, S. H. M., Zhou, J., Tan, T. K., Chen, L., Chng, W. J., & Teoh, P. J. (2024) · Blood · doi:10.1182/blood.2024024429 · Cited by 10
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
Mancuso, K., Barbato, S., Raimondo, F. D., Gay, F., Musto, P., Offidani, M., Petrucci, M. T., Zamagni, E., Zambello, R., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17071168 · Cited by 10
Thalidomide-induced limb malformations: an update and reevaluation
Collins, M. D., & Scott, W. J. (2025) · Archives of Toxicology · doi:10.1007/s00204-024-03930-z · Cited by 10
Targeted protein and protein-condensate degradation in plant science research and crop breeding
Niu, R., Luo, M., Wen, Q., Xiong, Y., Dang, H., & Xu, G. (2025) · Molecular Plant · doi:10.1016/j.molp.2025.06.013 · Cited by 10
Opportunities in proximity modulation: Bridging academia and industry
Đikić, I., Mayor‐Ruiz, C., Winter, G. E., Koch, K., Ciulli, A., & Thomä, N. H. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.07.018 · Cited by 11
Zhang, X., Dhruv, H., Deng, Q., Tudor, M., Bechtel, N., Nagilla, R., Jolivette, L. J., Rice, C., Orth, P., Behshad, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00668 · Cited by 10
Ion channel inhibition by targeted recruitment of NEDD4-2 with divalent nanobodies
Darko-Boateng, A., Afriyie, E., Morgenstern, T. J., Shanmugam, S. K., Zou, X., Laloudakis, Y. D., Choudhury, P., Desai, M., Kass, R. S., Vallese, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67068-x · Cited by 10
Wong, M. L., Murphy, J., Harrington, E. M., Gower, C. M., Jain, R. K., Schirle, M., & Thomas, J. R. (2016) · Proteome Science · doi:10.1186/s12953-017-0125-1 · Cited by 10
Agnarelli, A., Mitchell, S. A., Caalim, G., Wood, C. D., Milton‐Harris, L., Chevassut, T. J. T., West, M. J., & Mancini, E. J. (2022) · Hematological Oncology · doi:10.1002/hon.3016 · Cited by 10
Shen, C., Nayak, A., Neitzel, L. R., Yang, F., Li, B., Williams, C. H., Hong, C. C., Ahmed, Y. F., Lee, E. N., & Robbins, D. J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102227 · Cited by 10
Hui, J. Y., Fuchs, A., & Kumar, G. N. (2022) · Reproductive Toxicology · doi:10.1016/j.reprotox.2022.10.005 · Cited by 10
Applying CRISPR-Cas9 screens to dissect hematological malignancies
Iyer, D. N., Schimmer, A. D., & Chang, H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008966 · Cited by 10
Yan, J. W., & Zheng, Z. (2023) · ChemMedChem · doi:10.1002/cmdc.202200573 · Cited by 11
Hatakeyama, K., Kikushige, Y., Ishihara, D., Yamamoto, S., Kawano, G., Tochigi, T., Miyamoto, T., Sakoda, T., Christoforou, A., Kunisaki, Y., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010080 · Cited by 11
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
Chowdhury, B., Garg, S., Wei Min, N. I., Sattler, M., Sanchez, D., Meng, C., Akatsu, T., Stone, R. M., Forrester, W. C., Harrington, E. M., et al. (2024) · Cancers · doi:10.3390/cancers16071319 · Cited by 10
Solomon, L. A., Batista, C. R., & DeKoter, R. P. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.002 · Cited by 11
Akinjiyan, F. A., Fazal, A., Hild, M., Beckwith, R. E. J., Ross, N. T., Paulk, J., & Carbonneau, S. (2020) · SLAS DISCOVERY · doi:10.1177/2472555219901261 · Cited by 10
Interaction profiling methods to map protein and pathway targets of bioactive ligands
Huang, J., Coukos, J. S., & Moellering, R. E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.001 · Cited by 10
Yang, X., He, Y., Kim, R. D., Fleming, J. B., & Xie, H. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00782-2 · Cited by 11
Costacurta, M., Vervoort, S. J., Hogg, S. J., Martin, B. P., Johnstone, R. W., & Shortt, J. (2020) · Haematologica · doi:10.3324/haematol.2020.265611 · Cited by 11
Reboud‐Ravaux, M. (2021) · Biologie Aujourd hui · doi:10.1051/jbio/2021007 · Cited by 10
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H. J., Bertsch, U., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005532 · Cited by 10
Griffiths, E. A., Brady, W. E., Tan, W., Vigil, C. E., Thompson, J. E., Ford, L. A., Dickey, N. M., Bashaw, H. L., Sperrazza, J., Wetzler, M., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.02.003 · Cited by 11
Wakabayashi, S., Sawamura, N., Voelzmann, A., Broemer, M., Asahi, T., & Hoch, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.757823 · Cited by 10
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“…2012; weilemann et al. 2015). interestingly, iKZF1 and iKZF3 regulate the expression of iRF4 and c-Myc and their loss reduces the levels of these factors suggesting a therapeutic potential for targeting these proteins in blood malignancies (lu et al. 2014; Bjorklund et al. 2015) (Figure 5A, ii).”
Influential
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.